Estradiol enhances CIP2A expression by the activation of p70 S6 kinase

Endocrine-Related Cancer

Volumn 21, Issue 2, 2014, Pages 189-202

  Choi, Yeon A ^a   Koo, Ja Seung ^b   Park, Jeong Su ^a   Park, Mi Young ^a   Jeong, Ae Lee ^a   Oh, Ki Sook ^a   Yang, Young ^a  

^a Sookmyung Women's University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Breast cancer; CIP2A; ER positive human breast cancer cells; Estradiol (E2); MAPK pathway; P70 S6K; PI3K AKT

Indexed keywords

DACTINOMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; G PROTEIN COUPLED RECEPTOR 30; GEFITINIB; INITIATION FACTOR 4B; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN CIP2A; PROTEIN KINASE B; S6 KINASE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MCF 7 CELL LINE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

BREAST CANCER; CIP2A; ER-POSITIVE HUMAN BREAST CANCER CELLS; ESTRADIOL (E2); MAPK PATHWAY; P70 S6K; PI3K/AKT;

AUTOANTIGENS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, MESSENGER;

EID: 84899823528     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0453     Document Type: Article

References (53)

1. Acconcia F & Kumar R 2006 Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Letters 238 1-14. (doi:10.1016/j.canlet.2005.06.018)
2. Barletta F, Wong CW, McNally C, Komm BS, Katzenellenbogen B & Cheskis BJ 2004 Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Molecular Endocrinology 18 1096-1108. (doi:10.1210/me.2003-0335)
3. Basile JR & Czerninski R 2010 The role of CIP2A in oral squamous cell carcinoma. Cancer Biology & Thrapy 10 700-702. (doi:10.4161/cbt.10.7.13151)
4. Bockelman C, Hagstrom J, Makinen LK, Keski-Santti H, Hayry V, Lundin J, Atula T, Ristimaki A & Haglund C 2011a High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. British Journal of Cancer 104 1890-1895. (doi:10.1038/bjc.2011.167)
5. Bockelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Butzow R & Ristimaki A 2011b Prognostic role of CIP2A expression in serous ovarian cancer. British Journal of Cancer 105 989-995. (doi:10.1038/bjc.2011. 346)
6. Bockelman C, Koskensalo S, Hagstrom J, Lundin M, Ristimaki A & Haglund C 2012 CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biology & Therapy 13 289-295. (doi:10.4161/cbt. 18922)
7. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC et al. 2008 Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation 118 3065-3074. (doi:10.1172/JCI34739)
8. Chen XG, Liu F, Song XF, Wang ZH, Dong ZQ, Hu ZQ, Lan RZ, Guan W, Zhou TG, Xu XM et al. 2010 Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Molecular Carcinogenesis 49 603-610. (doi:10.1002/mc.20661)
9. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM et al. 2009 CIP2A is associated with human breast cancer aggressivity. Clinical Cancer Research 15 5092-5100. (doi:10.1158/1078- 0432.CCR-08-3283)
10. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ & Wang EH 2011 CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Annals of Surgical Oncology 18 857-865. (doi:10.1245/s10434-010-1313- 8)
11. Elston CW & Ellis IO 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 403-410. (doi:10.1111/j.1365-2559.1991.tb00229.x)
12. Ferreira PR, Fleck JF, Diehl A, Barletta D, Braga-Filho A, Barletta A & Ilha L 2004 Protective effect of a-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head & Neck 26 313-321. (doi:10.1002/hed.10382)
13. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B & Senn HJ 2011 Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology 22 1736-1747. (doi:10.1093/annonc/mdr304)
14. Gopalakrishna R, Gundimeda U, Fontana JA & Clarke R 1999 Differential distribution of protein phosphatase 2A in human breast carcinoma cell lines and its relation to estrogen receptor status. Cancer Letters 136 143-151. (doi:10.1016/S0304-3835(98)00315-2)
15. Hammond ME, Hayes DF, Wolff AC, Mangu PB & Temin S 2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Oncology Practice 6 195-197. (doi:10.1200/JOP.777003)
16. Huang LP, Adelson ME, Mordechai E & Trama JP 2010 CIP2A expression is elevated in cervical cancer. Cancer Biomarkers 8 309-317. (doi:10.3233/CBM- 2011-0220)
17. Huang LP, Savoly D, Sidi AA, Adelson ME, Mordechai E & Trama JP 2012a CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Medicine 1 76-81. (doi:10.1002/cam4.15)
18. Huang P, Qiu J, You J, Hong J, Li B, Zhou K, Chen G, Yuan Y & Zou R 2012b Expression and prognostic significance of CIP2A mRNA in hepato-cellular carcinoma and nontumoral liver tissues. Biomarkers 17 422-429. (doi:10.3109/1354750X.2012.680608)
19. Kumari Kanchan R, Tripathi C, Singh Baghel K, Kumar Dwivedi S, Kumar B, Sanyal S, Sharma S, Mitra K, Garg V, Singh K et al. 2012 Estrogen receptor potentiates mTORC2 signaling in breast cancer cells by upregulating superoxide anions. Free Radical Biology & Medicine 53 1929-1941. (doi:10.1016/j. freeradbiomed.2012.08.595)
20. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M, Khanna A, Chan EK, Kahari VM, Kellokumpu-Lehtinen PL et al. 2013 Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discovery 3 182-197. (doi:10.1158/2159-8290.CD-12-0292)
21. Levin ER 2003 Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Molecular Endocrinology 17 309-317. (doi:10.1210/me.2002-0368)
22. Lobenhofer EK, Huper G, Iglehart JD & Marks JR 2000 Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth & Differentiation 11 99-110.
23. Losel R & Wehling M 2003 Nongenomic actions of steroid hormones. Nature Reviews. Molecular Cell Biology 4 46-56. (doi:10.1038/nrm1009)
24. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR & Clark RE 2011 Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 117 6660-6668. (doi:10.1182/blood-2010-08-304477)
25. Magnuson B, Ekim B & Fingar DC 2012 Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochemical Journal 441 1-21. (doi:10.1042/BJ20110892)
26. Mallepell S, Krust A, Chambon P & Brisken C 2006 Paracrine signaling through the epithelial estrogen receptor a is required for proliferation and morphogenesis in the mammary gland. PNAS 103 2196-2201. (doi:10.1073/pnas. 0510974103)
27. McEwan MV, Eccles MR & Horsfield JA 2012 Cohesin is required for activation of MYC by estradiol. PLoS ONE 7 e49160. (doi:10.1371/journal.pone. 0049160)
28. Meyer MR, Haas E, Prossnitz ER & Barton M 2009 Non-genomic regulation of vascular cell function and growth by estrogen. Molecular and Cellular Endocrinology 308 9-16. (doi:10.1016/j.mce.2009.03.009)
29. Niemela M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernila P, Kallioniemi OP, Joensuu H, Hautaniemi S & Westermarck J 2012 CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 31 4266-4278. (doi:10.1038/onc.2011.599)
30. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M & Gustafsson JA 2001 Mechanisms of estrogen action. Physiological Reviews 81 1535-1565.
31. Pallai R, Bhaskar A, Sodi V & Rice LM 2012 Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Transcription 3 323-335. (doi:10.4161/trns.22518)
32. Pedram A, Razandi M & Levin ER 2006 Nature of functional estrogen receptors at the plasma membrane. Molecular Endocrinology 20 1996-2009. (doi:10.1210/me.2005-0525)
33. Pietras RJ 2003 Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast Journal 9 361-373. (doi:10.1046/j.1524-4741.2003.09510.x)
34. Pullen N & Thomas G 1997 The modular phosphorylation and activation of p70s6k. FEBS Letters 410 78-82. (doi:10.1016/S0014-5793(97)00323-2)
35. Qu W, Li W, Wei L, Xing L, Wang X & Yu J 2012 CIP2A is overexpressed in esophageal squamous cell carcinoma. Medical Oncology 29 113-118. (doi:10.1007/s12032-010-9768-9)
36. Radimerski T, Montagne J, Rintelen F, Stocker H, van der Kaay J, Downes CP, Hafen E & Thomas G 2002 dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nature Cell Biology4251-255. (doi:10.1038/ncb763)
37. Razandi M, Pedram A, Park ST & Levin ER 2003 Proximal events in signaling by plasma membrane estrogen receptors. Journal of Biological Chemistry 278 2701-2712. (doi:10.1074/jbc.M205692200)
38. Rogers GW Jr, Komar AA & Merrick WC 2002 eIF4A: the godfather of the DEAD box helicases. Progress in Nucleic Acid Research and Molecular Biology 72 307-331. (doi:10.1016/S0079-6603(02)72073-4)
39. Sarbassov DD, Ali SM & Sabatini DM 2005 Growing roles for the mTOR pathway. Current Opinion in Cell Biology 17 596-603. (doi:10.1016/j.ceb.2005.09. 009)
40. Shah OJ, Wang Z & Hunter T 2004 Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Current Biology 14 1650-1656. (doi:10.1016/j.cub. 2004.08.026)
41. Song RX, Chen Y, Zhang Z, Bao Y, Yue W, Wang JP, Fan P & Santen RJ 2010 Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 118 219-230. (doi:10.1016/j.jsbmb.2009.09.018)
42. Spielman A, Andreadis TG, Apperson CS, Cornel AJ, Day JF, Edman JD, Fish D, Harrington LC, Kiszewski AE, Lampman R et al. 2004 Outbreak of West Nile virus in North America. Science 306 1473-1475 author reply 1473-1475. (doi:10.1126/science.306.5701.1473c)
43. Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Chen PC, Lan YT et al. 2012 CIP2A is a predictor of poor prognosis in colon cancer. Journal of Gastrointestinal Surgery 16 1037-1047. (doi:10.1007/s11605-012-1828- 3)
44. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW & Chen KF 2012 CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Research 14 R68. (doi:10.1186/bcr3175)
45. Urruticoechea A, Smith IE & Dowsett M 2005 Proliferation marker Ki-67 in early breast cancer. Journal of Clinical Oncology 23 7212-7220. (doi:10.1200/JCO.2005.07.501)
46. Vaarala MH, Vaisanen MR & Ristimaki A 2010 CIP2A expression is increased in prostate cancer. Journal of Experimental & Clinical Cancer Research 29 136. (doi:10.1186/1756-9966-29-136)
47. Wang J, Li W, Li L, Yu X, Jia J & Chen C 2011 CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. International Journal of Laboratory Hematology 33 290-298. (doi:10.1111/j.1751-553X.2010.01288.x)
48. Wang L, Gu F, Ma N, Zhang L, Bian JM & Cao HY 2013 CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarci-noma. Tumour Biology 34 2309-2313. (doi:10.1007/s13277-013-0775-2)
49. Weng QP, Kozlowski M, Belham C, Zhang A, Comb MJ & Avruch J 1998 Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. Journal of Biological Chemistry 273 16621-16629. (doi:10.1074/jbc.273.26.16621)
50. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 25 118-145. (doi:10.1200/JCO.2006.09.2775)
51. Yu G, Liu G, Dong J & Jin Y 2013 Clinical implications of CIP2A protein expression in breast cancer. Medical Oncology 30 524. (doi:10.1007/s12032-013-0524-9)
52. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD & Kwiatkowski DJ 2007 PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. Journal of Clinical Investigation 117 730-738. (doi:10.1172/JCI28984)
53. Zhao D, Liu Z, Ding J, Li W, Sun Y, Yu H, Zhou Y, Zeng J, Chen C & Jia J 2010 Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways. Journal of Medical Microbiology 59 259-265. (doi:10.1099/jmm.0.014704-0)